Category: MassDevice Q&ASyndicate content

MassDevice Podcast: Neuronetics CEO Bruce Shook

August 27, 2011 by Arezu Sarvestani

Neuronetics president & CEO Bruce Shook on treating an incurable psychiatric disorder, chasing reimbursement and turning psychiatrists into medical device proceduralists.

NeuroStar Coil system
Neuronetics' NeuroStar TMS therapy system

Neuronetics Inc. is paving the way for a new type of depression therapy, a non-invasive electromagnetic field treatment designed to stimulate brain cells linked to depression.

Bruce Shook, co-founder, president & CEO, talked to MassDevice about pioneering the market for the only FDA-cleared transcranial magnetic stimulation system to date, his company's NeuroStar TMS system.

The therapy, which won the FDA nod in 2008, is a rarity in the med-tech world: A device-based approach to a psychiatric disorder.

MassDevice Exclusive: Former Medtronic CEO Hawkins on the Sprint Fidelis recall

August 22, 2011 by MassDevice staff

Former Medtronic CEO Bill Hawkins, in the second installment of an in-depth interview with, gives us an inside look at one of the most high-profile medical device recalls ever – the Sprint Fidelis pacemaker lead.

Former Medtronic CEO Bill Hawkins
Former Medtronic CEO Bill Hawkins at MassDevice
global headquarters.

In October 2007 Bill Hawkins was only three months into his tenure as CEO of the world's largest pure-play medical device maker when he faced the toughest choice of his career – cancel shipment on the company's top product, the Sprint Fidelis pacemaker lead, already implanted in some 268,000 patients – or stand pat and keep the potentially lethal products on the market.

MassDevice podcast: Calypso Medical CEO Ed Vertatschitsch

August 21, 2011 by Christian Holland

Calypso Medical Techechnologies CEO Ed Vertatschitsch on the company's tumor-tracking radiation therapy, "GPS for the Body," why the company tackled prostate cancer first and what organs may be next.

Ed Vertatschitsch

Calypso Medical Technologies Inc. treated its 10,000th prostate cancer patient with GPS for the Body in May, an important landmark for the Seattle-based targeted radiation therapy company and its flagship device.

GPS for the Body won FDA clearance in 2006 for focused prostate cancer radiation therapy using a proprietary guidance system that tracks a tumor in real time as the body moves, keeping the radiation beam on target.

MassDevice Exclusive: Former CEO Hawkins on leaving Medtronic

August 17, 2011 by MassDevice staff

Former Medtronic CEO Bill Hawkins, in the first installment of an in-depth interview with, tells us why the time had come for him to leave the world's largest pure-play device maker – and fills us in on his plans for the future.

Former Medtronic CEO Bill Hawkins

Bill Hawkins

They gave him a sword and he handed them the world.

When William Hawkins officially flipped the keys to Medtronic Inc. (NYSE:MDT) over to successor Omar Ishrak, he offered a simple message and a gift. The message was clear – don't lose sight of founder Earl Bakken's mission to alleviate pain, restore health and extend life while "striving without reserve for the greatest possible reliability and quality."

What keeps you up at night? | The MassDevice Big 100 Regional Roundtable CEO Panel

August 15, 2011 by MassDevice staff

Industry leaders discuss the challenges facing their fields and in medical devices as a whole at the MassDevice Big 100 Regional Roundtable.

Regional Roundtable

Med-tech leaders came together for a meeting of the minds at MassDevice's first Big 100 Regional Roundtable in Waltham, Mass., July 11. Four CEOs, each representing an interesting and important sector of the life science industry – the fascinating juncture between orthopedics and minimally invasive techniques, genomics and personalized medicine, the cutting edge of bio-interactive nanotech coatings and the mid-cap medical device world – shared their thoughts on the particular challenges facing their businesses and the life sciences industry as a whole.

Cancer: Allegro Diagnostics hunts lung cancer's "canary in the coal mine"

August 15, 2011 by Arezu Sarvestani

Allegro Diagnostics is in clinical trials for its flagship diagnostic assay, designed to detect the early stages of lung cancer, the deadliest cancer on the planet.

Avrum Spira in the clinic

Dr. Avrum Spira in the clinic

If Allegro Diagnostics' clinical trials go as planned, the Maynard, Mass.-based company will be on its way to commercializing a test to detect the "canary in the coal mine" of the planet's deadliest cancer: Early-stage lung cancer.

With a patented molecular diagnostic assay, Allegro co-founder and Boston University associate professor Avrum Spira has garnered over $3.5 million in funding from the National Institutes of Health and $8.9 million from investors.

MassDevice Podcast: Covidien's Joe Almeida at the MassDevice Big 100 Roundtable

July 25, 2011 by Brian Johnson

The new CEO of Covidien plc, Jose "Joe" Almeida, speaks with MassDevice publisher Brian Johnson about his vision for the company at the MassDevice Big 100 Regional Roundtable in this exclusive interview.

Joe Almeida

Covidien CEO Joe Almeida at the MassDevice Big 100 Regional Roundtable, July 11, 2011

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp